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Summary The bisphosphonates are able to relieve pain from metastatic bone disease and, when given
intravenously, may promote bone healing of lytic metastases. In this study, the aim was to assess the acute
effects of a single 'high-dose' intravenous treatment with pamidronate on pain, mobility, analgesic consump-
tion and quality of life (QOL). Thirty-four normocalcaemic patients with painful progressing bone metastases
(22 from breast, five prostate and seven others) received a single intravenous infusion of 120 mg of pami-
dronate as palliative therapy. No other systemic therapy or drugs known to influence bone metabolism were
administered during the study. Patients' subjective response to treatment was assessed weekly with a pain
questionnaire recording a composite of pain intensity, mobility, performance status and analgesic consump-
tion. In addition, patients completed the Rotterdam Symptom Check List (RSCL) for measurement of QOL
and a mobility questionnaire. The mean reduction in the pain questionnaire score (recorded on at least two
occasions) was 25% [standard error (s.e.) 3%, range 0-75%]. Twenty patients (59%) showed a ,20%
improvement and were classified as responders. The median duration of symptomatic response was 12 (range
4-24 +) weeks. The responding patients showed a reduction in RSCL score (improvement in QOL) from 35%
before treatment to 27% at 6 weeks, but no significant improvement was noted in non-responders. Twenty-one
patients were retreated with pamidronate when their symptoms deteriorated again. Eight out of 15 responders
showed a second reduction in pain score of 20%, but this was not seen in any of the six non-responders.
Five patients have remained well with no additional treatment for their disease other than repeat infusions of
pamidronate every 3-6 months. Treatment was well tolerated. Eight (24%) experienced fever after the first
treatment only, and four had asymptomatic, biochemical evidence of hypocalcaemia. The acute inhibition of
osteoclastic bone resorption induced by a single high-dose treatment with pamidronate can provide useful
palliation for patients with bone metastases. Responding patients may be retreated as symptoms dictate to
good effect. We are currently running a phase III double-blind trial with high-dose pamidronate for
progressive painful metastatic bone disease to exclude any placebo effect and observer bias.
Bone metastases are common in advanced cancer and cause
significant skeletal morbidity with pain, pathological frac-
tures, hypercalcaemia and increasing disability (Coleman &
Rubens, 1987). Treatment includes analgesics, palliative
radiotherapy, orthopaedic procedures and appropriate syste-
mic treatment. However, relief of symptoms is only tem-
porary and many patients face a period of increasing
disability, pain and deterioration in quality of life. For those
with breast or prostate cancer, diseases characterised by a
relatively slow clinical course and a special affinity for meta-
stasis to bone, many months or even years of effective palli-
ative therapy is essential to maintain a good quality and
useful life.
In recent years it has become recognised that activation of
osteoclasts, the normal bone-resorbing cells, is the fundamen-
tal process underlying the development and progression of
bone metastases. Inhibition of osteoclast activity with the
bisphosphonates is therefore a logical treatment (Coleman &
Purohit, 1993). The bisphosphonates are now firmly estab-
lished as the treatment of choice for hypercalcaemia of malig-
nancy (Ralston et al., 1985), have been shown to relieve pain
and promote bone healing when given intravenously (Col-
eman et al., 1988; Morton et al., 1988; Burckhardt et al.,
1989; Grabelsky et al., 1991; Tyrrell et al., 1993) and are able
to prevent complications of skeletal involvement when given
by mouth (Paterson et al., 1993; van Holton-Verzantvoort et
al., 1993).
Previously, intravenous treatment has been given in
relatively small doses on a repeated basis (Coleman et al.,
1988; Morton et al., 1988; Burckhardt et al., 1989; Grabelsky
et al., 1991; Tyrrell et al., 1993). The aim of this study was to
assess the effect of a single 'high-dose' intravenous treatment
with pamidronate on pain, mobility, analgesic consumption,
quality of life and bone metabolism.
Picuts and method
Thirty-four patients with progressing symptomatic, radio-
graphically confirmed bone metastases were entered into this
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open phase II study. Twenty-two patients had metastatic
bone disease arising from the breast, five from the prostate,
two Ewing's sarcoma and one each from the bronchus, blad-
der, kidney, malignant melanoma and an unknown
primary.
All patients were heavily pretreated with radiotherapy to
multiple metastatic sites. Twenty-seven of 34 patients had
received prior endocrine treatment and 12 out of 34
chemotherapy (Table I). Two patients with prostate cancer
had also received treatment with the radioisotope strontium-
89. Two patients had received previous bisphosphonate
therapy with oral clodronate, but this had been discontinued
more than 3 months before commencing pamidronate.
The patients were treated with a single intravenous
infusion of pamidronate 120 mg in 1 1 of 0.9% normal saline.
Initially this was given on an inpatient basis over 12 h, but
recently six patients have received treatment as outpatients
over 2 h, and all follow-up courses are now given on this
schedule. No other systemic treatment was prescribed.
Patients progressing on endocrine therapy continued with
these agents to avoid the possibility of a withdrawal re-
sponse. Analgesics were prescribed as necessary, and patients
referred for palliative radiotherapy if pain could not be ade-
quately controlled with analgesics. Patients reporting im-
provement or stabilisation of symptoms were to be retreated
on demand with the same dose of pamidronate.
Patients were followed-up in the outpatients department
every 2 weeks for 8 weeks and then monthly thereafter. Prior
to commencing therapy, and at each clinic visit, a bio-
chemical and haematological screen was performed and an
early morning sample of urine collected for measurement of
calcium and hydroxyproline excretion. Patients were asked to
complete a pain questionnaire (Table II), the Rotterdam
Symptom Checklist (RSCL) Quality of Life (QOL) measure
(De Haes et al., 1990) and a modified form of the Oswestry
Mobility Questionnaire (Fairbank et al., 1980) relating pain
to daily and social activities. In addition, the WHO perfor-
mance status was recorded (WHO, 1979). The first three
parameters were recorded by the patient (with the help of a
research nurse) every week for the first 4 weeks, then every
fortnight for a month and on a monthly basis thereafter, and
the performance status at each outpatient attendance.
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Table I Previous treatments
Tumour type Radiotherapy Endocrine Cytotoxic Strontium-89 Clodronate
Breast 22 21 10 0 1
Prostate 5 5 0 2 1
Other 7 1 2 0 0
Total 34 27 12 2 2
aTwo Ewing's sarcoma, one melanoma, one non-small-cell lung cancer, one bladder, one kidney,
one unknown primary.
Table H Derivation of a symptomatic assessment from a patient-completed
questionnaire and distribution of scores at baseline
No. of
Parameter Description Score patients




Very severe 4 2
Intolerable 5 6
Analgesic use None 0 0
Simple analgesic or NSAID' 1 6
Simple analgesic + NSAID 2 1
Moderate analgesic (e.g. dihydrocodeine) 3 7
Opiates (<40mg of morphine daily) 4 4
Opitates (40-100mg of morphine daily) 5 3
Opiates (>I00mg of morphine daily) 6 13
Performance status Normal 0 1
Light work possible 1 1
Up and about >50% of the day 2 13
Confined to bed >50% of the day 3 19
Completely bed-bound 4 0
Symptom score expressed as a percentage of maximum total 15 (100%)
'NSAID, non-steroidal anti-inflammatory drug.
Table HI Subjective response to treatment
Responders No change Progression
Tumour type (>20% reduction) (0-20% reduction) (increase in pain)
Breast 15 (68%) 7 (32%) 0
Prostate 3 (60%) 2 (40%) 0
Other 2 (29%) 5 (71%) 0
Total 20 (59%) 14 (41%) 0
'Two Ewing's sarcoma, one melanoma, one non-small cell hmg cancer, one
bladder, one kidney, one uninown primary.
For each visit, the scores for pain, analgesic consumption
and performance status were combined to produce an overall
symptom score. Patients were classified as symptomatic re-
sponders if they reported a >20% reduction from baseline
in this symptom score on at least two consecutive assess-
ments. For the RSCL, the scores for the functional, physical
and psychological domains were alculated separately and
expressed as a percentage of the maximum score possible.
Similarly, for the Oswestry Pain Questionnaire, the scores
were expressed as a percentage of the maximum score pos-
sible.
Reits
The mean reduction in the pain questionnaire score following
a single pamidronate treatment was 25% [standard error
(s.e.) 3%, range 0-75%]. Twenty patients (59%) showed a
> 20% improvement and were classified as responders (Table
III). Figure 1 shows the pain score following treatment ex-
pressed as a percentage of baseline (mean values ± s.e.). The
median duration of symptomatic response was 12 (range
4-24 +) weeks. None of the responding patients received
palliative radiotherapy to any site during this symptomatic
response. However, one patient classed as a responder com-
menced pamidronate within 2 weeks of a course of radio-
therapy to spinal metastases, and the latter may have
contributed to the response observed.
Table IV shows changes in the assessment of quality of life
and mobility. At 4 weeks a 12% reduction from baseline
(absolute reduction 4.1%) in the mean overall QOL score
was seen, attributable to improvements in the physical and
psychological domains rather than functional. Those patients
showing a subjective response to treatment, as defined above,
recorded a significant reduction in RSCL score (improvement
in QOL) from 35% (s.e. 3.5%) before treatment to 29% (s.e.
3.1%) at 4 weeks. No significant improvement was observed
in the non-responders. The Oswestry Questionnaire also
showed a reduction in the mean percentage score, from 52%
(s.e. 3.1%) to 43% (s.e. 3.0%) indicating a reduction in the
impact of pain on normal social function and activities of
daily living (P = < 0.01).
Treatment was well tolerated with minor symptoms occurr-
ing only after the first treatment. Eight patients (24%)
experienced fever and transient rigors after the first infusion
but this did not occur on subsequent treatments. One patient
experienced diarrhoea and another nausea and vomiting.
Four patients had biochemical evidence of hypocalcaemia
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Table IV Serial values for the Rotterdam Symptom Checklist (RSCL)
Quality of Life Assessments and the Oswestry Mobility Questionnaires.
Values are mean percentages of maximum possible scores
Week on study
0 1 2 3 4 6 8
RSCL
All patients 34 34 33 32 32 28 23
Psychological domain 30 29 28 28 24 23 23
Physical domain 30 28 25 25 24 22 22
Functional domain 48 48 46 49 48 42 41
All domains 36 35 33 34 32b 29b 29b
Responders 20 20 20 20 20 20 15
All domains 35 34 31 32 29 27b 26b
Non-responders 14 14 13 12 12 8 8
All domains 38 36 34 36 35 33 34
Oswestry score 34 34 33 32 32 28 23
52 44' 44' 44' 43' 41' 38'
aP = <0.01 vs baseline. bp = <0.05 vs basehne.
(adjusted calcium 1.89-2.01 mmol 1-1). No patient experi-
enced symptomatic hypocalcaemia. As expected, urinary cal-
cium excretion fell significantly following treatment (Figure
2) and remained below the baseline value for 4-24 + weeks
(median 12 weeks).
Theoretically, rapid infusion of large doses of pamidronate
could lead to hypocalcaemia. In five of the patients receiving
pamidronate over 2 h, we measured the total and non-ionised
levels of calcium before and immediately after the infusion of
pamidronate. The mean total serum calcium was 2.28 [stan-
dard deviation (s.d.) of 0.14] mmol 1' before treatment and
2.21 (s.d. 0.10) mmol 1' after the infusion, and the ionised
serum calcium 1.22 (s.d. 0.04) mmol l' and 1.15 (s.d.
0.08) mmol I' before and after treatment respectively.
To date, 21 patients have been retreated. Eight out of 15
responders to their initial treatment showed a second reduc-
tion in pain score of >20%, but this was not seen in any of
the six non-responders. Five patients have remained well with
maintained symptomatic response for more than a year with
no additional treatment for their disease other than repeat
infusions of pamidronate every 3-6 months.
Disasssion
The bisphosphonates are an important advance in the treat-
ment of metastatic bone disease, producing symptomatic
relief (Coleman et al., 1988; Morton et al., 1988; Burckhardt
et al., 1989; Grabelsky et al., 1991; Ernst et al., 1992; Tyrrell
et al., 1993) and preventing skeletal morbidity (Paterson et
al., 1993; van Holton-Verzantvoort et al., 1993). For pain
relief parenteral treatment has proved most effective, with
oral therapy limited somewhat by problems of poor absorp-
tion and gastrointestinal toxicity. To date, this has required
regular outpatient visits to receive infusions of bisphos-
phonate, and in the studies mentioned above intravenous
pamidronate was given every 2-4 weeks as the only systemic
treatment for patients with metastatic bone disease. All of
these studies reported similar results, with subjective benefit
occurring in about one half of patients.
It is well recognised that the majority of an intravenous
infusion of pamidronate is adsorbed onto the bone surface
(Daley Yates et al., 1991) where it remains bound to hy-
droxyapatite for a very long time - probably years.
Therefore, a single infusion can theoretically have a pro-
longed duration of action on the osteoclast, causing sustained
inhibition of bone resorption. Indeed this is seen following
treatment of Paget's disease of bone (Fitton & McTavish,
1991). Our study has shown a high frequency of symptomatic
response, achieved following a single infusion of a relatively
high dose of pamidronate. Fifty-nine per cent of patients
reported useful benefit lasting several weeks, and this could
be reinduced by repeat treatments. The improvements in
quality of life, as measured by the RSCL, and reduction in
the social and functional impact of pain, shown by the
Oswestry Questionnaire, provide additional evidence for the
beneficial effects of treatment.
Our results support a small pilot study from South Africa
where patients received a single infusion of 90 mg of pamid-
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1991). Previous studies have also reported healing of lytic
metastases in approximaely one-quarter of patients (Cokman
& Purohit, 1993; Tyrell et al., 1993). In our present study
however, the patients had sclerotic or mixed lytic/sclerotic
metastases, making radiographic assessment unrehable, so we
are unable to comment on the structural effects of single
doses.
Retreatment of these patients was originally intended to be
'on dand' for those showing subjective benefit. However,
six patients who failed to meet our criteria for response also
received a second treatment. Interestingly, a second response
was seen only in those showing symptomatic response to the
first treatment. The bisphosphonates are expensive drugs and,
although confirmatory studies are needed, our data suggest
that the most cost-efficient use of bisphosphonates is to lmit
repeated treatment to those who have shown a clear subjec-
tive response to the first treatment.
The ability to be able to achieve symptomatic response in
sclerotic metastatic bone disease through selective inhibition
of bone resorption is an important clinical observation and
confirms previous small studies with pamidronate (Clarke et
al., 1991) and clodronate (Adami & Mian, 1989) in prostate
cancer. This effect is possible because there is always an
important lytic component present (even in patients with
predominantly sclerotic metastases on plain radiographs) in
which the osteolysis can only be demonstrated either histo-
logically or in some instances, by computerised tomographic
(CT) scanning (Galasko, 1976; Colman, 1991). The sclerotic
radiographic appearances mask the uncoupling and im-
balance of bone remodelling that occurs in many patients
with bone metastases, with the excessive new bone formation
occurring away from sites of osteoclastic bone resorption.
Most probably it is the lytic component that causes meta-
static bone pain, as pain is not a major feature of conditions
such as osteopetrosis or myelofibrosis in which pure bone
sclerosis occurs.
As in previous studies, it is unclear why only some patients
respond to pamidronate. Inhibition of bone resorption, as
measured by urinary calcium excretion, occurs in >95% of
patients after 120 mg of pamidronate, and most also show a
reduction in other markers of bone resorption such as col-
lagen pyridinium cross-links and hydroxyproline excretion
(Purohit et al., in press). No relationship between sympto-
matic and biochemial response could be determined. Subjec-
tive response appeared to be unrelated to tumour type, the
type of bone metastases as evident on radiological examina-
tion (i.e. lytic, sclerotic and/or mixed lytic and sclerotic) or
amount or type of previous systemic treatment. The pretreat-
ment pain score was slightly lower in responding patients
than non-responders (8.7 vs 10.9), but this difference did not
reach statistical signifinc.
The maximum safe dose of pamidronate has never been
defined. In the only published phase I study of pamidronate,
Body et al. (1987) a six different dose levels for the
treatment of hypercalaemia of malignancy. Treatment was
well tolerated except for one obese patient who received a
total dose of 285mg of pamidronate (3mglkg') infused
over 2 h, and in whom fever and hypotension were reported.
In our series, treatment was safe, even when given over 2 h,
and well tokrated. Although all our patients were normocal-
caemic at the beginning of the pamidronate infusion,
sigificant hypocacaemia was not a problem. Four out of 34
patients showed biochemical evidence of hypocalaemia, but
this was of no clinical signifi and reverted to normal in
3-4 weeks. There may be scope for further dose escalation in
the future. Whether this could lead to a greater or more
sustained response to treatment is not known but, in view of
the very long half-life of bisphosphonates in bone, is worthy
of future study with a view to reducing hospital visits for
palliative therapy to a minimum.
There was no evidence of renal toxicity with either the 12
or the 2 h infusions of pamidronate, and in particular the
three patients with renal impairment before treatment (123,
172 and 238 plmol 1- respectively) toklrated treatment
equally well.
This study adds further to the increasing number of pub-
lications identifying the bisphosphonates as a useful addition
to the range of palliative treatments for metastatic bone
disease. There remains the possibility of a placebo response
contributing to our results, and having shown that this treat-
ment is feasible and well tolerated we are now conducting a
randomised placebo-controlled study. Nevertheless, for the
majority of this cohort of heavily pretrated patients, out-
patient treatment with intravenous high-dose pamidronate
was a valuable new treatment approach.
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